These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 18413834)
1. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Bex A; de Gast G; Haanen JB; Boven E Clin Cancer Res; 2008 Apr; 14(8):2431-6. PubMed ID: 18413834 [TBL] [Abstract][Full Text] [Related]
2. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib. Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239 [TBL] [Abstract][Full Text] [Related]
3. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471 [TBL] [Abstract][Full Text] [Related]
4. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. Rini BI; Garcia J; Elson P; Wood L; Shah S; Stephenson A; Salem M; Gong M; Fergany A; Rabets J; Kaouk J; Krishnamurthi V; Klein E; Dreicer R; Campbell S J Urol; 2012 May; 187(5):1548-54. PubMed ID: 22425095 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123 [TBL] [Abstract][Full Text] [Related]
7. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Gorin MA; Ekwenna O; Soloway MS; Ciancio G Urology; 2012 Feb; 79(2):e11. PubMed ID: 21676439 [TBL] [Abstract][Full Text] [Related]
8. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579 [TBL] [Abstract][Full Text] [Related]
16. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278 [TBL] [Abstract][Full Text] [Related]
17. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy. Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788 [TBL] [Abstract][Full Text] [Related]
18. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. Lainakis G; Bamias A; Psimenou E; Fountzilas G; Dimopoulos MA Clin Nephrol; 2009 Jul; 72(1):73-8. PubMed ID: 19640391 [TBL] [Abstract][Full Text] [Related]
19. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. Silberstein JL; Millard F; Mehrazin R; Kopp R; Bazzi W; DiBlasio CJ; Patterson AL; Downs TM; Yunus F; Kane CJ; Derweesh IH BJU Int; 2010 Nov; 106(9):1270-6. PubMed ID: 20394613 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]